Epocrates Drug Updates — Editor’s Pick
November 04, 2009
MedWatch Safety Alert for Byetta
The FDA issued an emergency use authorization (EUA) for the investigational intravenous neuraminidase inhibitor, peramivir, for use in children and adults with known or suspected infection with influenza A 2009 H1N1 virus. This unapproved product should be used only for hospitalized patients who are unresponsive to or unable to take oral or inhaled antiviral therapies, or when IV therapy is deemed clinically appropriate.
MedWatch Safety Alert for Byetta
Recent Updates
- October 28, 2009
- New Drug Monograph for Peramivir
The FDA issued an emergency use authorization (EUA) for the investigational intravenous neuraminidase inhibitor, peramivir, for use in children and adults with known or suspected infection with influenza A 2009 H1N1 virus. This unapproved product should be used only for hospitalized patients who are unresponsive to or unable to take oral or inhaled antiviral therapies, or when IV therapy is deemed clinically appropriate. New Drug Monograph for Peramivir » - October 21, 2009
- New Drug Monograph for Folotyn
The new folate antagonist, Folotyn (pralatrexate), was recently approved for adult patients with relapsed or refractory peripheral T-cell lymphoma. New Drug Monograph for Folotyn » - October 14, 2009
- MedWatch Safety Alert for Relenza
The FDA notified healthcare professionals that Relenza (zanamivir) is intended for use only with the Diskhaler device provided with the drug product. The powder should not be removed from its packaging or reconstituted in liquid formulations for use in any nebulizer or mechanical ventilator. The safety, efficacy, and stability of Relenza via nebulizer has not been established. Additionally, nebulized formulations can obstruct proper functioning of mechanical ventilator equipment, posing a safety risk for patients. MedWatch Safety Alert for Relenza »
New Drug Monographs
These updates, and hundreds more, are available in all Epocrates mobile and online products. See Products
To update your mobile reference, simply Update (sync). Learn How